What is it about?

PGLP-1, a newly designed dual-function GLP-1 analog, reduces gluconeogenesis and promotes insulin secretion as well as other GLP-1 agonists.

Featured Image

Why is it important?

We found that PGLP-1, as a bifunctional peptide, can reduce the blood glucose in streptozotocin-induced hyperglycemia mice, so it can be used as adjuvant therapy for T1DM.


I wish to develop long acting of PGLP-1 to a permanent treatment in the future

Dr Murad Alahdal
Johns Hopkins University

Read the Original

This page is a summary of: PGLP-1, a novel long-acting dual-function GLP-1 analog, ameliorates streptozotocin-induced hyperglycemia and inhibits body weight loss, The FASEB Journal, August 2017, Federation of American Societies For Experimental Biology (FASEB),
DOI: 10.1096/fj.201700002r.
You can read the full text:



The following have contributed to this page